Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Kodiak Sciences Inc(KOD)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KOD
09/15/2026: KOD (3-star) is currently NOT-A-BUY. Pass it for now.
Kodiak Sciences is a clinical-stage biotechnology company focused on developing long-acting, proprietary treatments for retinal diseases. Its primary strength lies in its Antibody Biopolymer Conjugate platform, which seeks to improve drug durability and efficacy. The main investment story centers on the potential of its pipeline, specifically candidates like KSI-501, to disrupt the established retinal treatment market. Key risks include the lack of commercial revenue, significant cash burn, and the high hurdle posed by well-entrenched competitors. This stock is best suited for risk-tolerant, long-term investors monitoring clinical trial data and the company's capital management strategy, as success is contingent on binary development outcomes.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential high growth if clinical trials succeed, but carries high risk. |
| Momentum investor | Weak fit | Momentum is often erratic and tied to binary clinical event outcomes. |
| Value investor | Weak fit | The lack of earnings and commercial products makes traditional value assessment inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on R&D. |
| Low-risk investor | Weak fit | High clinical and financial risks make this unsuitable for low-risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results often cause drastic stock price movements. |
| Valuation risk | High | Valuation is speculative and based on future potential rather than current cash flow. |
| Competition risk (Ophthalmology) | High | Established players hold dominant positions with standard-of-care treatments. |
| Business quality | Medium | The underlying science is strong, but the business is not yet commercially viable. |
| Dividend income | Low / none | No income potential exists for shareholders. |
| Execution risk | High | The firm must successfully navigate complex regulatory and clinical hurdles to succeed. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 1075.19% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.07B USD | Price to earnings Ratio - | 1Y Target Price 69.6 |
Price to earnings Ratio - | 1Y Target Price 69.6 | ||
Volume (30-day avg) 599.1K shares | Beta 2.18 | 52 Weeks Range 9.10 - 47.84 | Updated Date 09/15/2026 |
52 Weeks Range 9.10 - 47.84 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.17 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Retinal Therapeutics R&D | Clinical development of drug candidates like tarcocimab and KSI-501. | The company currently makes no money; it burns cash to develop drugs that hope to reach the market. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2.01B | Price to Sales(TTM) - |
Enterprise Value 2.01B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding 62.85M | Shares Floating 39.56M |
Shares Outstanding 62.85M | Shares Floating 39.56M | ||
Percent Insiders 5.16 | Percent Institutions 102.42 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Kodiak Sciences Inc
Exchange NASDAQ | Headquarters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Chairman, CEO & President Dr. Victor Perlroth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 141 | Website https://kodiak.com |
Full time employees 141 | Website https://kodiak.com | ||
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.